Key result
LMWH matches unfractionated heparin efficacy and safety in venous thrombosis with more convenient administration.
Answers are grounded in this paper and cite their sources.
Review summarizes the pharmacology and clinical efficacy of low-molecular-weight heparin versus unfractionated heparin in venous thrombosis, highlighting improved convenience and safety.
Heparin is one of the oldest biological medicines, and has an established place in the prevention and treatment of venous thrombosis. Low-molecular-weight heparins (LMWH) have been developed by several manufacturers and have advantages in terms of pharmacokinetics and convenience of administration. They have been shown to be at least as effective and safe as unfractionated heparin and have replaced the latter in many indications. In this article the chemistry, mechanisms of action, measurement of anticoagulant activities, and clinical status of heparin and LMWH are reviewed.
No takes yet. Share an insight, caveat, or question.
Mulloy et al. (2008) conducted a review in Venous thrombosis. Low-molecular-weight heparin vs. Unfractionated heparin was evaluated. Low-molecular-weight heparins are at least as effective and safe as unfractionated heparin for venous thrombosis, offering improved pharmacokinetics and administration convenience.
Synapse has enriched 10 related papers. Consider them for comparative context: